Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention (DAWN)

This study is ongoing, but not recruiting participants.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
Lynn E. Fiellin, Yale University Identifier:
First received: October 20, 2010
Last updated: September 29, 2016
Last verified: January 2016
This is a double-blind placebo-controlled study to evaluate the effect of Naltrexone (NTX) and counseling on highly active antiretroviral treatment (HAART) medication adherence in a cohort of HIV-infected patients who report heavy drinking, or meet criteria for alcohol abuse and/or dependence, and inadequate (< 95%) HAART adherence. All patients will receive a behavioral intervention, termed Medical Management/Medication Coaching or MM/MC. MM/MC incorporates the behavioral platform Medical Management (MM) from the National Institute on Alcohol Abuse and Alcoholism (NIAAA)-funded COMBINE Study to reduce heavy alcohol use with Medication Coaching (MC), a manualized treatment designed to improve HAART medication adherence in HIV-infected patients with substance use disorders.

Condition Intervention Phase
Reduction in Heavy Drinking in Patients With HIV
Drug: Naltrexone
Other: Placebo + Medication Management/Medication Coaching
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • To compare the efficacy of NTX +MM/MC versus placebo +MM/MC on adherence to HAART. [ Time Frame: One year ]
    NTX +MM/MC will lead to improved adherence to HAART when compared to placebo + MM/MC.

Secondary Outcome Measures:
  • To compare the efficacy of NTX +MM/MC versus placebo +MM/MC in reducing days of heavy drinking. [ Time Frame: One year ]
    NTX +MM/MC will lead to greater reductions in the number of days of heavy drinking when compared to placebo + MM/MC.

Estimated Enrollment: 154
Study Start Date: April 2011
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: NTX + MM/MC
Naltrexone + Medical Management/Medication Coaching
Drug: Naltrexone
NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
Other Name: Vivitrol
Placebo Comparator: Placebo + MM/MC
Placebo plus Medical Management/Medication Coaching
Other: Placebo + Medication Management/Medication Coaching
Placebo + Medication Management/Medication Coaching


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be HIV-infected.
  2. Currently be prescribed HAART medication or be eligible to receive HAART medication.
  3. Report less than 95% adherence to their HAART medication.
  4. Report heavy drinking 4 or more times in the past 4 weeks, or meet current criteria for alcohol abuse or dependence. Heavy drinking is defined as 4 or more drinks for women and 5 or more drinks for men on one occasion.
  5. Be at least 18 years old.
  6. Be able to understand English and provide informed consent.

Exclusion Criteria:

  1. Be psychotic or severely psychiatrically disabled.
  2. Be currently enrolled in formal treatment for alcohol (excluding self-help, e.g. Alcoholics Anonymous)
  3. Have medical conditions that would preclude completing or be of harm during the course of the study.
  4. Have laboratory or clinical evidence of significant liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of the normal range) or cirrhosis with a Child-Pugh classification greater than A or B.
  5. Have a known contraindication to NTX therapy (e.g. requiring opioid medication for pain).
  6. Be pregnant, nursing or unable to use an effective method of birth control (women).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01227044

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
VACT Healthcare System
New Haven, Connecticut, United States, 06516
Sponsors and Collaborators
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Lynn E Sullivan (Fiellin), MD Yale University
  More Information

Responsible Party: Lynn E. Fiellin, Associate Professor, Yale University Identifier: NCT01227044     History of Changes
Other Study ID Numbers: HIC0909005730
1R01AA018923 ( US NIH Grant/Contract Award Number )
Study First Received: October 20, 2010
Last Updated: September 29, 2016

Keywords provided by Yale University:
Substance Abuse Counseling
Adherence (medication)
Alcohol Abuse
Highly Active Antiretroviral Therapy (HAART)

Additional relevant MeSH terms:
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on May 22, 2017